London, UK (PRWEB) August 20, 2015
Originator biologics represent the most expensive drugs, with many of them costing approximately USD 100,000 per patient per annum. Such drugs are not highly affordable and that is why some patients cannot be treated by them. Besides, patent protection for some of such biologics has run out and patent rights will be lost by a number of originator biologics over the next few years.
That is why biotechnology companies start focusing on developing and marketing biosimilars, which are being highly-similar versions of biological drugs. Besides, a cost benefit of biosimilars for biotechnology companies ranges from 20 to 30 percent.
Biosimilars entered the EU marketplace in 2006 and they are present in such markets as South Korea, India and China. They have also become available in the USA, following an approval of the first biosimilar by FDA in H1 2015. The number of biosimilars available in the US market is set to grow significantly in the upcoming years.
The US market may dethrone the EU which is currently the world’s largest market for biosimilars. There are nearly 44 biosimilars are available in the global marketplace.
New research report “Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations and Strategic Outlook” drawn up by Kelly Scientific Publications is now available at MarketPublishers.com.
Title: Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations and Strategic Outlook
Published: August, 2015
Price: US$ 3,400.00
The research report offers an insightful analysis of the biosimilars marketplace, with a special focus made on the USA. The report contains a detailed overview of the market, explores the regulatory landscape and sheds light on biosimilars’ development trends. The study covers biobetters and shares with a reader valuable data on approved biosimilars. It discusses impact of biosimilars on originators and concentrates on top ten biologics. The report explores five major classes of originator biologies and analyses their market performance. The research study profiles market players and looks at their products. Future market outlook can be found in the report, too.
- insightful overview of the marketplace;
- coverage of the regulatory landscape;
- profiles of biosimilar developers;
- overview of approved biosimilars;
- and more.
More new reports by the publisher can be found at Kelly Scientific Publications page.